摘要
目的评估miR-21和miR-135对前列腺癌筛查的临床价值。方法选取2016年8月至2018年6月我院收治的前列腺癌(PCa)患者、良性前列腺增生(BPH)患者和同时期体检正常的健康人群各80例,分别纳入PCa组、BPH组和健康组。采用实时荧光定量PCR法检测各组血清中miR-21和miR-135的表达水平,分析其对PCa的诊断价值。结果PCa组miR-21和miR-135的表达水平均明显高于BPH组和健康组(P<0.05),BPH组和健康组间差异无统计学意义(P>0.05);Gleason评分>7分的PCa患者血清miR-21和miR-135表达水平均明显高于Gleason评分≤7分的患者(P<0.05)。结论miR-21和miR-135在PCa患者血清中呈高表达,可作为PCa筛查、辅助诊断和预后评估的分子标志物。
Objective To evaluate the clinical value of microRNA-21 and microRNA-135 in screening for prostate cancer (PCa). Methods From August 2016 to June 2018, 80 patients with PCa, 80 patients with benign prostatic hyperplasia (BPH) and 80 healthy people were selected and enrolled in PCa group, BPH group and healthy group respectively. Real-time fluorescence quantitative polymerase chain reaction was used to detect the expression levels of microRNA-21 and microRNA-135 in serum of each group, and its diagnostic value for PCa was analyzed. Results The expression levels of microRNA-21 and microRNA-135 in PCa group were significantly higher than those in BPH group and healthy group ( P <0.05). There was no significant difference between BPH group and healthy group ( P >0.05). The expression levels of serum microRNA-21 and microRNA-135 in PCa patients with Gleason score>7 were significantly higher than those in patients with Gleason score≤7 ( P <0.05). Conclusions MicroRNA-21 and microRNA-135 are highly expressed in the serum of PCa patients and can be used as molecular markers for PCa screening, auxiliary diagnosis and prognosis evaluation.
作者
王威
孙克
WANG Wei;SUN Ke(Clinical Laboratory,East Hospital of Baoding First Central Hospital,Baoding 071000,China)
出处
《现代泌尿生殖肿瘤杂志》
2019年第2期109-111,共3页
Journal of Contemporary Urologic and Reproductive Oncology
